Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: SENSORION

Market Cap 128M 149M 118M 111M 209M 14.11B 211M 1.4B 544M 6.92B 559M 547M 23.92B P/E Ratio 2026 *
-16.6x
P/E Ratio 2027 * -3.84x
Enterprise Value -3.58M -4.15M -3.29M -3.09M -5.81M -393M -5.88M -38.88M -15.15M -193M -15.58M -15.25M -666M EV / Sales 2026 *
-0.16x
EV / Sales 2027 * 20.1x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%+1.04%-13.08%-12.43% 43.58B
-2.17%+5.45%+285.76%+522.83% 34.03B
+0.44%-2.46%+14.20%-17.35% 29.77B
-1.60%-2.54%-2.12%+31.28% 29.82B
-0.29%+9.47%+13.95%+21.93% 25.42B
+3.54%+12.34% - - 13.87B
-1.26%+0.81%+54.77%+109.24% 13.35B
-1.04%-3.33%+3.98%+3.91% 12.85B
-1.18%-0.61%+105.37%+75.32% 12.22B
Average -0.41%+2.03%+57.85%+91.84% 23.88B
Weighted average by Cap. -0.54%+2.02%+59.38%+102.72%

Financials

2026 *2027 *
Net sales 21.86M 25.38M 20.12M 18.9M 35.5M 2.4B 35.91M 238M 92.59M 1.18B 95.2M 93.18M 4.07B 6.4M 7.42M 5.89M 5.53M 10.39M 703M 10.51M 69.49M 27.09M 345M 27.85M 27.26M 1.19B
Net income -4.34M -5.04M -4M -3.75M -7.05M -477M -7.13M -47.16M -18.39M -234M -18.9M -18.5M -808M -50.64M -58.79M -46.62M -43.79M -82.25M -5.56B -83.19M -550M -215M -2.73B -221M -216M -9.43B
Net Debt -132M -153M -122M -114M -214M -14.5B -217M -1.43B -559M -7.12B -575M -563M -24.59B -
Logo SENSORION
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!